Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Scilex Holding Company ( (SCLX) ) just unveiled an update.
On February 19, 2026, Scilex Holding Company entered into a Warrant Agreement with Oramed Pharmaceuticals Inc., under which Oramed agreed to defer an October 1, 2025 amortization payment on Scilex’s Tranche B senior secured convertible notes in exchange for a new warrant to purchase 100,000 shares of Scilex common stock at an initial exercise price of $20.00 per share. The deferred payment was ultimately made in November 2025, and the February 2026 Warrant, which is immediately exercisable and expires on December 13, 2029, includes anti-dilution adjustments, ownership caps of up to 9.99%, change-of-control protections with a Black-Scholes-based cash repurchase right, and registration commitments for the underlying shares, collectively strengthening Oramed’s protections while giving Scilex incremental flexibility in managing its liabilities and equity over time.
More about Scilex Holding Company
Scilex Holding Company operates in the biopharmaceutical sector, focusing on pain management therapies and related pharmaceutical products. The company’s capital structure includes senior secured convertible notes and equity-linked securities, reflecting an active use of structured financing to support its operations and growth initiatives.
Average Trading Volume: 83,541
Technical Sentiment Signal: Sell
Current Market Cap: $69.8M
For an in-depth examination of SCLX stock, go to TipRanks’ Overview page.